Analysis of Esophageal cancer patients who have received chemotherapy before Surgery

Not Applicable

• Conditions: Health Condition 1: null- Esophageal Cancer Patients

• Registration Number: CTRI/2017/05/008491
• Lead Sponsor: il

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

We will include all patients who have esophageal cancer and evidence of airway involvement, who are planned for induction chemotherapy, followed by reassessment.

Airway involvement is defined as at least one of the following criteria:

1. Bronchoscopic appearance of external compression or bulge into the tracheal or bronchial lumen, in a patient in whom upfront chemoradiotherapy or radiotherapy was not offered, and who was planned for induction chemotherapy

2. Bronchoscopic appearance of restricted mobility or immobility of the mucosa of the trachea or bronchi, in a patient in whom upfront chemoradiotherapy or radiotherapy was not offered, and who was planned for induction chemotherapy

3. Bronchoscopic appearance of endotracheal or endobronchial tumor.

4. Clinical diagnosis of stridor, when other causes of stridor have been ruled out and the cause of stridor is clinically due to airway obstruction.

We will include patients who have started chemotherapy from Nov 2010 onwards to 15 Jan 2015.

Exclusion Criteria

Patients who are planned for palliative intent therapy or best supportive care.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess the impact of induction chemotherapy in patients with esophageal cancer and airway involvement, in terms of the ability to deliver curative intent therapy. <br/ ><br>Timepoint: 10-12 weeks

Secondary Outcome Measures

Name	Time	Method
1.Overall survival <br/ ><br>2.Progression-free survival <br/ ><br>3.Response rate <br/ ><br>4.Evaluate factors that affect toxicity. <br/ ><br>5.Evaluate factors that affect survival. <br/ ><br>6.Rate of development of TEF during induction chemotherapy. <br/ ><br>7.Rate of development of TEF during definitive intent therapy. <br/ ><br>Timepoint: 10- 12 weeks